Skip to main
RCEL
RCEL logo

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical's strong financial performance in the fourth quarter, with commercial revenue reaching $18.4 million and a year-over-year increase of 30%, highlights the company’s effective market penetration and product adoption for its RECELL system. The impressive gross profit margin of 87.6% reflects AVITA's pricing power and operational efficiency, positioning the company favorably within the acute wound care market. Looking forward, the combination of recent FDA approvals, expanded production capabilities, and strategic commercialization efforts suggests that AVITA is well-equipped to achieve accelerated revenue growth and capture more market share.

Bears say

Avita Medical's reliance on a single product, the RECELL system, may pose significant risks, particularly given its limited market penetration outside the US and a focus on burn centers, which could restrict growth potential. The decision to not actively market in established markets like Australia, Europe, Canada, and China further limits revenue diversification opportunities, placing heavy reliance on the US market's performance. Additionally, the adjustment of the price target from $25.00 to $22.00 indicates a cautious outlook reflecting potential concerns about future sales growth and market expansion.

RCEL has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Buy based on their latest research and market trends.

According to 6 analysts, RCEL has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.